DOI QR코드

DOI QR Code

Endoscopic submucosal dissection for superficial esophageal squamous cell carcinoma: long-term follow-up in a Western center

  • Andreas Probst (Department of Gastroenterology, University Hospital Augsburg) ;
  • Alanna Ebigbo (Department of Gastroenterology, University Hospital Augsburg) ;
  • Stefan Eser (Department of Gastroenterology, University Hospital Augsburg) ;
  • Carola Fleischmann (Department of Gastroenterology, University Hospital Augsburg) ;
  • Tina Schaller (Institute of Pathology and Molecular Diagnostics, University Hospital Augsburg) ;
  • Bruno Markl (Institute of Pathology and Molecular Diagnostics, University Hospital Augsburg) ;
  • Stefan Schiele (Institute of Mathematics and Computational Statistics, University of Augsburg) ;
  • Bernd Geissler (Department of General, Visceral and Transplant Surgery, University Hospital Augsburg) ;
  • Gernot Muller (Institute of Mathematics and Computational Statistics, University of Augsburg) ;
  • Helmut Messmann (Department of Gastroenterology, University Hospital Augsburg)
  • Received : 2022.03.05
  • Accepted : 2022.04.29
  • Published : 2023.01.30

Abstract

Background/Aims: Endoscopic submucosal dissection (ESD) has been established as a treatment modality for superficial esophageal squamous cell carcinoma (ESCC). Long-term follow-up data are lacking in Western countries. The aim of this study was to analyze long-term survival in a Western center. Methods: Patients undergoing ESD for ESCC were included. The analysis was performed retrospectively using a prospectively collected database. Results: R0 resection rate was 96.7% (59/61 lesions in 58 patients). Twenty-seven patients (46.6%) fulfilled the curative resection criteria (M1/M2) (group A), 11 patients (19.0%) had M3 lesions without lymphovascular invasion (LVI) (group B), and 20 patients (34.5%) had lesions with submucosal invasion or LVI (group C). Additional treatment was recommended after non-curative resection. It was not performed in 20/31 patients (64.5%), mainly because of comorbidities (75%). Twenty-nine out of 58 (50.0%) patients died during a mean follow-up of 3.7 years. Death was related to ESCC in 17.2% (5/29) of patients. The disease-specific survival rate after curative resection was 100%. Overall survival rates after 5 years were 61.5%, 63.6% and 28.1% for groups A, B, and C, respectively. The overall survival was significantly worse after non-curative resection (p=0.038). Conclusions: Non-curative resection is frequent after ESD for ESCC in Western patients. The long-term prognosis is limited and mainly determined by comorbidity. Early diagnosis and pre-interventional assessments need to be improved.

Keywords

References

  1. Ferlay J, Ervik M, Lam F, et al. Global cancer observatory: cancer today. Lyon: International Agency for Research on Cancer; 2020 [cited 2021 Jul 11]. Available from: https://gco.iarc.fr/today/online-analysis-map?v=2020&mode=population&mode_population=continents&population=900&populations=900&key=asr&-sex=0&cancer=6&type=0&statistic=5&prevalence=0&population_group=0&ages_group%5B%5D=0&ages_group%5B%5D=17&nb_items=10&group_cancer=1&include_nmsc=0&include_nmsc_other=0&projection=natural-earth&color_palette=default&map_scale=quantile&map_nb_colors=5&continent=0&show_ranking=0&rotate=%255B10%252C0%255D. 
  2. Arnold M, Ferlay J, van Berge Henegouwen MI, et al. Global burden of oesophageal and gastric cancer by histology and subsite in 2018. Gut 2020;69:1564-1571. 
  3. Probst A, Aust D, Markl B, et al. Early esophageal cancer in Europe: endoscopic treatment by endoscopic submucosal dissection. Endoscopy 2015;47:113-121. 
  4. Oyama T, Tomori A, Hotta K, et al. Endoscopic submucosal dissection of early esophageal cancer. Clin Gastroenterol Hepatol 2005;3(7 Suppl 1):S67-S70. 
  5. Takahashi H, Arimura Y, Masao H, et al. Endoscopic submucosal dissection is superior to conventional endoscopic resection as a curative treatment for early squamous cell carcinoma of the esophagus (with video). Gastrointest Endosc 2010;72:255-264. 
  6. Pimentel-Nunes P, Dinis-Ribeiro M, Ponchon T, et al. Endoscopic submucosal dissection: European Society of Gastrointestinal Endoscopy (ESGE) Guideline. Endoscopy 2015;47:829-854. 
  7. Kitagawa Y, Uno T, Oyama T, et al. Esophageal cancer practice guidelines 2017 edited by the Japan esophageal society: part 2. Esophagus 2019;16:25-43. 
  8. Ishihara R, Arima M, Iizuka T, et al. Endoscopic submucosal dissection/endoscopic mucosal resection guidelines for esophageal cancer. Dig Endosc 2020;32:452-493. 
  9. Endoscopic Classification Review Group. Update on the Paris classification of superficial neoplastic lesions in the digestive tract. Endoscopy 2005;37:570-578. 
  10. Veitch AM, Vanbiervliet G, Gershlick AH, et al. Endoscopy in patients on antiplatelet or anticoagulant therapy, including direct oral anticoagulants: British Society of Gastroenterology (BSG) and European Society of Gastrointestinal Endoscopy (ESGE) guidelines. Endoscopy 2016;48:385-402. 
  11. Yamaguchi N, Isomoto H, Nakayama T, et al. Usefulness of oral prednisolone in the treatment of esophageal stricture after endoscopic submucosal dissection for superficial esophageal squamous cell carcinoma. Gastrointest Endosc 2011;73:1115-1121. 
  12. Probst A, Ebigbo A, Markl B, et al. Stricture prevention after extensive endoscopic submucosal dissection of neoplastic Barrett's esophagus: individualized oral steroid prophylaxis. Gastroenterol Res Pract 2019;2019:2075256. 
  13. Cotton PB, Eisen GM, Aabakken L, et al. A lexicon for endoscopic adverse events: report of an ASGE workshop. Gastrointest Endosc 2010;71:446-454. 
  14. Kim JS, Kim BW, Shin IS. Efficacy and safety of endoscopic submucosal dissection for superficial squamous esophageal neoplasia: a meta-analysis. Dig Dis Sci 2014;59:1862-1869. 
  15. Repici A, Hassan C, Carlino A, et al. Endoscopic submucosal dissection in patients with early esophageal squamous cell carcinoma: results from a prospective Western series. Gastrointest Endosc 2010;71:715-721. 
  16. Lorenzo D, Barret M, Leblanc S, et al. Outcomes of endoscopic submucosal dissection for early oesophageal squamous cell neoplasia at a Western centre. United European Gastroenterol J 2019;7:1084-1092. 
  17. Fleischmann C, Probst A, Ebigbo A, et al. Endoscopic submucosal dissection in Europe: results of 1000 neoplastic lesions from the German Endoscopic Submucosal Dissection Registry. Gastroenterology 2021;161:1168-1178. 
  18. Iwai N, Dohi O, Yamada S, et al. Prognostic risk factors associated with esophageal squamous cell carcinoma patients undergoing endoscopic submucosal dissection: a multi-center cohort study. Surg Endosc 2022;36:2279-2289. 
  19. Park CH, Yang DH, Kim JW, et al. Clinical practice guideline for endoscopic resection of early gastrointestinal cancer. Clin Endosc 2020;53:142-166. 
  20. Oyama T, Inoue H, Arima M, et al. Prediction of the invasion depth of superficial squamous cell carcinoma based on microvessel morphology: magnifying endoscopic classification of the Japan Esophageal Society. Esophagus 2017;14:105-112. 
  21. Katada C, Tanabe S, Wada T, et al. Retrospective assessment of the diagnostic accuracy of the depth of invasion by narrow band imaging magnifying endoscopy in patients with superficial esophageal squamous cell carcinoma. J Gastrointest Cancer 2019;50:292-297. 
  22. Hatta W, Koike T, Takahashi S, et al. Risk of metastatic recurrence after endoscopic resection for esophageal squamous cell carcinoma invading into the muscularis mucosa or submucosa: a multicenter retrospective study. J Gastroenterol 2021;56:620-632. 
  23. Kim GH, Na HK, Ahn JY, et al. Long-term outcomes and factors affecting the survival of patients with mucosal esophageal squamous cell carcinoma. Gut Liver 2021;15:705-712.